The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance).
 
Sara Char
Consulting or Advisory Role - Goodpath
 
Qian Shi
Honoraria - Chugai Pharma
Consulting or Advisory Role - Hoosier Cancer Research Network; Kronos Bio; Mirati Therapeutics; Regeneron; Yiviva
Research Funding - BMS (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Regeneron (Inst); Roche/Genentech (Inst)
 
Tyler Zemla
No Relationships to Disclose
 
Chao Ma
No Relationships to Disclose
 
En Cheng
Employment - Kaiser Permanente
 
Priya Kumthekar
Stock and Other Ownership Interests - EnClear Therapies
Consulting or Advisory Role - Affinia Therapeutics; Belay Diagnostics; Biocept; BioClinica; Biodexa; BPGbio; EnClear Therapies; FYR Diagnostics; IN8bio; Novocure; Plus Therapeutics; SDP Oncology; Seagen; SERVIER; Telix Pharmaceuticals
Speakers' Bureau - Seagen
Research Funding - Angiochem; DNAtrix; Genentech; Novocure; Orbus Therapeutics
Patents, Royalties, Other Intellectual Property - Utility patent for ANG 1005. No financial gain, no royalties.
 
Katherine Guthrie
No Relationships to Disclose
 
Felix Couture
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis Canada Pharmaceuticals Inc
 
J. Kuebler
Consulting or Advisory Role - Advarra
 
Pankaj Kumar
No Relationships to Disclose
 
Benjamin Tan
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck Serono (Inst); Tvardi Therapeutics (Inst); TYME (Inst)
 
Smitha Krishnamurthi
Consulting or Advisory Role - Agenus; Bristol-Myers Squibb; Takeda
Research Funding - Agenus (Inst); Aravive (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for two chapters I have written in UptoDate
 
Brian Wolpin
Consulting or Advisory Role - Agenus; EcoR1 Capital; Harbinger Health; Ipsen; Mirati Therapeutics; Revolution Medicines; Tango Therapeutics; Third Rock Ventures
Research Funding - Agios; Amgen; Amgen; AstraZeneca (Inst); Harbinger Health (Inst); Lilly (Inst); Novartis (Inst); Revolution Medicines (Inst)
 
Francois Geoffroy
No Relationships to Disclose
 
Fred Tabung
No Relationships to Disclose
 
Anthony Shields
Consulting or Advisory Role - Caris Life Sciences; Cogent Biosciences; ImaginAb; Legend Biotech
Speakers' Bureau - Caris Life Sciences
Research Funding - Abbisko Therapeutics (Inst); Alkermes; Amal Therapeutics (Inst); Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; Gritstone Bio (Inst); H3 Biomedicine; Halozyme; Hutchison China Meditech; IconOVir Bio (Inst); ImaginAb; Incyte; Inovio Pharmaceuticals; Jiangsu Alphamab Biopharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Nuvation Bio (Inst); Plexxikon; Repertoire Immune Medicines; Seagen; Shanghai HaiHe Pharmaceutical; Sorrento Therapeutics (Inst); SQZ Biotechnology (Inst); Taiho Pharmaceutical; Telix Pharmaceuticals; TheraBionic (Inst); TopAlliance BioSciences Inc (Inst); Torque (Inst); Xencor
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget
 
Eileen O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); Revolution Medicines; SERVIER (I); Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Revolution Medicines (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Jeffrey Meyerhardt
Employment - Dana-Farber Cancer Institute; Newton Wellesley Hospital (I)
Speakers' Bureau - Research to Practice
 
Chen Yuan
No Relationships to Disclose
 
Kimmie Ng
Honoraria - GlaxoSmithKline; Seagen
Consulting or Advisory Role - Abbvie; Agenus; AstraZeneca; Bayer; CytomX Therapeutics; Etiome; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Pfizer; Revolution Medicines
Research Funding - Janssen (Inst); Pharmavite (Inst)
Expert Testimony - Crico
Other Relationship - jama